

14<sup>th</sup> World Congress on

# Toxicology and Pharmacology

March 12-14, 2018 Singapore

, QÀXH QFH RI LPPXQH PRGXODWLRQ E\ WXPRU FHOO GHULYH

Mohammad Amjad Hossain, Adithan Aravinthan, Judith Sharmila, Bumseok Kim, Chang Won Kang, Nam Soo Kim and Jong-Hoon Kim  
Chonbuk National University, South Korea

Cancer has been viewed as a disease consisting of transformed cells, of hyper proliferative, invasive and immortal nature. Accordingly, the anti-cancer strategies are also focused on tumor cells only. In the present study, the gastric cancer cell line (SNU-484) soluble compounds have been evaluated for its immunosuppression properties. The proteins present in the SNU-484 soluble compounds (SC) were identified with human cytokine array. The effect of SC on rat splenocytes has been studied with special emphasis on NK cell activity. In results, the addition of various concentration of SC did not show any significant apoptotic or proliferation changes when compared to untreated control splenocytes. Further the incubation of splenocytes with SC reduced the expression of NK cell markers at the transcription level. The same scenario was observed ~~in vitro study~~ following 2 days of treatment. Incubation of splenocytes with SC for a longer period reduced the cytotoxic ability, further this observation was strengthened by the reduction of CD135 (NK) cells in SC treatment. In addition tests were performed to check whether SC can increase tumor formation in allogenic tumor model. The B16F10 melanoma cells-injected animals developed tumor in 3 weeks, whilst the SC injected animals along B16F10 cells aggravates tumor formation, by increasing the PI3K/AKT levels. These findings clearly demonstrate that the presence of SC can modulate immune system response that favors the tumor formation.

## Biography

ORKDPPDG \$PMDG +RVVDLQ KDV FRPSOHWHG KLV JUDGXDWLRQ IURP 8QLYHUVLW\ RI 'HYHORSPHQW \$O \$FFHV V '2, & KRQEXN 1DWLRQDO 8QLYHUVLW\ 6FKRRO RI 9HWHULQDU\ 0HGLFLQH 6RXWK .RUHD +H

mamjadh2@gmail.com

Notes: